Two isogenic human iPSC lines, designated as iPSC28 (control) and IVS10 + 16 (tau-mutant), were employed as a proof of concept to assess, in a humanized in vitro model, the efficacy of detecting pathological tau forms using BT1-loaded NPM-HumAfFt in the retina of neurodegenerative disease patients. Here, MAPT is linked to neurodegenerative disease.